Volunteers wanted for study on alcohol’s effects
SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.
SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
Lack of sleep can lead to a range of cognitive, attention, and emotional deficits. SRI and its partner have made a thorough study of its effects on the brain.
SRI’s Sleep Research Laboratory in Menlo Park, California is currently recruiting for this study.
SRI’s Brown Laboratory is utilizing cell-targeting peptides to deliver active therapeutic cargo to specific cells in vivo.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
Researchers are seeking to identify novel genes contributing to nicotine metabolism and to smoking cessation.
SRI is developing a novel point-of-care tool for the early detection of devastating diseases.
SRI is seeking new treatments for tuberculosis, a global health crisis.
SRI’s Brown Laboratory is using selected peptides as “fishing hooks” to identify novel cell surface features.
SRI is investigating novel methods and treatments to improve cognitive deficits caused by diseases such as Alzheimer’s and depression.
SRI is developing a new therapeutic agent for influenza virus infections.
Innovative Science Overcomes Formulation Challenges
SRI is elucidating the mechanism of action of the drug of choice for the treatment of all known forms of human schistosomiasis.
SRI is enabling and improving metabolomics research with high-quality reference standards.
SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.
SRI takes an integrated approach to understand the systems that control sleep and wakefulness.
A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.
Partnering to Advance Therapy for Radiation Exposure
Partnering to Rapidly Advance ZMapp® for Ebola Treatment
To support more effective cessation treatments, SRI researchers are exploring how nicotinic receptors affect brain activity in response to smoking.
SRI is investigating whether the nicotine in tobacco smoke may be useful in meeting the urgent need to manage Parkinson’s disease.
This project could advance drug abuse prevention and intervention research by identifying Genetic x Environment (GxE) interactions, which may help explain the development of nicotine dependence. Results may guide development of tailored interventions.
Sleep complaints are common during the transition to menopause, yet we have little understanding of what drives this increase in sleep disturbance and how best to treat it. SRI researchers are investigating sleep quality in women who have begun to go through menopause.
Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.
SRI researchers are searching for new molecular targets that allow for discovery of more selective anticancer agents.
SRI is developing a method to enable rapid, large-scale response to a bioterrorism threat or an infectious disease epidemic.
SRI's Brown Laboratory is taking multiple approaches to develop effective anti-cancer immunotherapies.
For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.
SRI is analyzing the genetics of smoking and related characteristics, using data from a large-scale National Cancer Institute study on smoking cessation.
SRI sleep researchers are working to discover and develop new treatments for narcoleptic patients.
SRI established the Twin Research Registry as part of its scientific research and efforts to discover more about human behavior. Fraternal and identical twins and multiples of all ages are invited to join the Registry for consideration for research studies.
Using synthetic lethality to ID biomarkers for targeted anti-cancer drugs.
SRI studied twins to gain more clinical insight into physiologic response to powerful opioid painkillers. Study results should help to optimize pain relief and minimize adverse effects.
To help prepare for next-generation pandemics, SRI is partnering with Stanford University to examine vaccination responses.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.